Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

9 evidence topics · 11 sources

Phase 1b landmark radiographic progression-free survival by prior therapy
Cohort (rinzimetostat 400 mg once daily plus darolutamide)Landmark rPFS at 3, 4, and 5 monthsMedian follow-up
Previously treated with abiraterone“93%, 84%, and 84% at 3, 4, and 5 months”“4.9 months”
Previously treated with AR inhibitors“93%, 85%, and 85% at 3, 4, and 5 months”“4.8 months”